Patents by Inventor Kunihiko Kiyono
Kunihiko Kiyono has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10292962Abstract: Provided is a novel medicament capable of reducing the side effects of metformin or a pharmaceutically acceptable salt thereof and useful as an anti-malignant tumor agent, in which metformin or a pharmaceutically acceptable salt thereof and dihydroquercetin or a pharmaceutically acceptable salt thereof are combined.Type: GrantFiled: October 3, 2017Date of Patent: May 21, 2019Assignee: RESEARCH INSTITUTE FOR NUTRITION AND AGING CO., LTD.Inventors: Kunihiko Kiyono, Kenji Onishi, Yasuharu Nagahama, Takashi Watanabe
-
Publication number: 20180353466Abstract: Provided is a novel medicament capable of reducing the side effects of metformin or a pharmaceutically acceptable salt thereof and useful as an anti-malignant tumor agent, in which metformin or a pharmaceutically acceptable salt thereof and dihydroquercetin or a pharmaceutically acceptable salt thereof are combined.Type: ApplicationFiled: August 21, 2018Publication date: December 13, 2018Applicant: RESEARCH INSTITUTE FOR NUTRITION AND AGING CO., LTD.Inventors: Kunihiko KIYONO, Kenji ONISHI, Yasuharu NAGAHAMA, Takashi WATANABE
-
Publication number: 20180050014Abstract: Provided is a novel medicament capable of reducing the side effects of metformin or a pharmaceutically acceptable salt thereof and useful as an anti-malignant tumor agent, in which metformin or a pharmaceutically acceptable salt thereof and di-hydroquercetin or a pharmaceutically acceptable salt thereof are combined.Type: ApplicationFiled: October 3, 2017Publication date: February 22, 2018Applicant: RESEARCH INSTITUTE FOR NUTRITION AND AGING CO., LTD.Inventors: Kunihiko KIYONO, Kenji ONISHI, Yasuharu NAGAHAMA, Takashi WATANABE
-
Publication number: 20180036280Abstract: Provided is a novel medicament capable of reducing the side effects of metformin or a pharmaceutically acceptable salt thereof and useful as an anti-malignant tumor agent, in which metformin or a pharmaceutically acceptable salt thereof and dihydroquercetin or a pharmaceutically acceptable salt thereof are combined.Type: ApplicationFiled: October 3, 2017Publication date: February 8, 2018Applicant: RESEARCH INSTITUTE FOR NUTRITION AND AGING CO., LT D.Inventors: Kunihiko KIYONO, Kenji ONISHI, Yasuharu NAGAHAMA, Takashi WATANABE
-
Patent number: 9808440Abstract: Provided is a novel medicament capable of reducing the side effects of metformin or a pharmaceutically acceptable salt thereof and useful as an anti-malignant tumor agent, in which metformin or a pharmaceutically acceptable salt thereof and dihydroquercetin or a pharmaceutically acceptable salt thereof are combined.Type: GrantFiled: May 23, 2014Date of Patent: November 7, 2017Assignee: RESEARCH INSTITUTE FOR NUTRITION AND AGING CO., LTD.Inventors: Kunihiko Kiyono, Kenji Onishi, Yasuharu Nagahama, Takashi Watanabe
-
Publication number: 20160101082Abstract: Provided is a novel medicament capable of reducing the side effects of metformin or a pharmaceutically acceptable salt thereof and useful as an anti-malignant tumor agent, in which metformin or a pharmaceutically acceptable salt thereof and dihydroquercetin or a pharmaceutically acceptable salt thereof are combined.Type: ApplicationFiled: May 23, 2014Publication date: April 14, 2016Inventors: Kunihiko KIYONO, Kenji ONISHI, Yasuharu NAGAHAMA, Takashi WATANABE
-
Publication number: 20120322807Abstract: The present invention provides a STAT3/5 activation inhibitor containing an aromatic compound represented by the general formula or a salt thereof as an active ingredient: Wherein X1 represents a nitrogen atom or a group —CH?, R1 represents a group —Z—R6, in which Z represents a group —CO—, a group —CH(OH)— or the like, R6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents a groupType: ApplicationFiled: June 18, 2012Publication date: December 20, 2012Inventors: Kazuo Sekiguchi, Takashi Suzuki, Yutaka Ohbuchi, Mitsuhiro Okuno, Naoto Ohi, Kenji Ohnishi, Masaaki Motoyama, Kenji Yoshida, Takeshi Kodama, Kazuhisa Sugiyama, Seiji Akamatsu, Kunihiko Kiyono, Yasuo Yanagihara, Takashi Watanabe, Kazuhiko Hayashi, Hideo Tanaka, Takumi Sumida
-
Publication number: 20120238750Abstract: The compound of the present invention is represented by the following general formula (1): [wherein X1 represents a nitrogen atom or a group —CH?; R1 represents a group —Z—R6, wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R4 represents an imidazolyl lower alkyl group or the like.Type: ApplicationFiled: February 29, 2012Publication date: September 20, 2012Inventors: Tae FUKUSHIMA, Shuji Matsumura, Noriaki Takemura, Hideaki Satou, Nobuaki Ito, Takuya Shitsuta, Hironori Tsutsui, Michinori Tanaka, Keizo Kan, Hitoshi Nagao, Kenji Watanabe, Kuninori Tai, Takashi Nakagawa, Hideki Takasu, Makoto Sakamoto, Keisuke Miyajima, Satoshi Yamada, Yutaka Kojima, Koichi Yasumura, Naoto Ohi, Mitsuhiro Okuno, Kazuhisa Sugiyama, Kunihiko Kiyono, Takashi Suzuki, Seiji Akamatsu, Takeshi Kodama, Yasuo Yanagihara, Takumi Sumida
-
Patent number: 8263599Abstract: An object of the present invention is to provide a STAT3/5 activation inhibitor. The present invention provides a STAT3/5 activation inhibitor containing an aromatic compound represented by the general formula or a salt thereof as an active ingredient: wherein X1 represents a nitrogen atom or a group —CH?, R1 represents a group —Z—R6, in which Z represents a group —CO—, a group —CH(OH)— or the like, R6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents a group wherein R3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R4 represents an imidazolyl lower alkyl group or the like.Type: GrantFiled: October 2, 2007Date of Patent: September 11, 2012Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Kazuo Sekiguchi, Takashi Suzuki, Yutaka Ohbuchi, Mitsuhiro Okuno, Naoto Ohi, Kenji Ohnishi, Masaaki Motoyama, Kenji Yoshida, Takeshi Kodama, Kazuhisa Sugiyama, Seiji Akamatsu, Kunihiko Kiyono, Yasuo Yanagihara, Takashi Watanabe, Kazuhiko Hayashi, Hideo Tanaka, Takumi Sumida
-
Patent number: 8188277Abstract: The present invention provides a novel compound, which has an excellent effect of suppressing the generation of collagen and less side effects, with being excellent in terms of safety. The compound of the present invention is represented by the following general formula (1): [wherein X1 represents a nitrogen atom or a group —CH?; R1 represents a group —Z—R6, wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R4 represents an imidazolyl lower alkyl group or the like.Type: GrantFiled: August 3, 2005Date of Patent: May 29, 2012Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Tae Fukushima, Shuji Matsumura, Noriaki Takemura, Hideaki Satou, Nobuaki Ito, Takuya Shitsuta, Hironori Tsutsui, Michinori Tanaka, Keizo Kan, Hitoshi Nagao, Kenji Watanabe, Kuninori Tai, Takashi Nakagawa, Hideki Takasu, Makoto Sakamoto, Keisuke Miyajima, Satoshi Yamada, Yutaka Kojima, Koichi Yasumura, Naoto Ohi, Mitsuhiro Okuno, Kazuhisa Sugiyama, Kunihiko Kiyono, Takashi Suzuki, Seiji Akamatsu, Takeshi Kodama, Yasuo Yanagihara, Takumi Sumida
-
Publication number: 20100210661Abstract: An object of the present invention is to provide a STAT3/5 activation inhibitor. The present invention provides a STAT3/5 activation inhibitor containing an aromatic compound represented by the general formula or a salt thereof as an active ingredient: wherein X1 represents a nitrogen atom or a group —CH?, R1 represents a group —Z—R6, in which Z represents a group —CO—, a group —CH(OH)— or the like, R6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents a group wherein R3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R4 represents an imidazolyl lower alkyl group or the like.Type: ApplicationFiled: October 2, 2007Publication date: August 19, 2010Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kazuo Sekiguchi, Takashi Suzuki, Yutaka Ohbuchi, Mitsuhiro Okuno, Naoto Ohi, Kenji Ohnishi, Masaaki Motoyama, Kenji Yoshida, Takeshi Kodama, Kazuhisa Sugiyama, Seiji Akamatsu, Kunihiko Kiyono, Yasuo Yanagihara, Takashi Watanabe, Kazuhiko Hayashi, Hideo Tanaka, Takumi Sumida
-
Publication number: 20070270422Abstract: The present invention provides a novel compound, which has an excellent effect of suppressing the generation of collagen and less side effects, with being excellent in terms of safety. The compound of the present invention is represented by the following general formula (1): [wherein X1 represents a nitrogen atom or a group —CH?; R1 represents a group -Z-R6, wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R4 represents an imidazolyl lower alkyl group or the like.Type: ApplicationFiled: August 3, 2005Publication date: November 22, 2007Inventors: Tae Fukushima, Shuji Matsumura, Noriaki Takemura, Hideaki Satou, Nobuaki Ito, Takuya Shitsuta, Hironori Tsutsui, Michinori Tanaka, Keizo Kan, Hitoshi Nagao, Kenji Watanabe, Kuninori Tai, Takashi Nakagawa, Hideki Takasu, Makoto Sakamoto, Keisuke Miyajima, Satoshi Yamada, Yutaka Kojima, Koichi Yasumura, Naoto Ohi, Mitsuhiro Okuno, Kazuhisa Sugiyama, Kunihiko Kiyono, Takashi Suzuki, Seiji Akamatsu, Takeshi Kodama, Yasuo Yanagihara, Takumi Sumida
-
Patent number: 5516777Abstract: This invention provides a condensed pyrazole derivative of the Formula (1): ##STR1## (where A denotes CH or N, R.sup.0 and R.sup.3 denote same or different, a hydrogen atom or a lower alkyl group, R.sup.1 and R.sup.2 denote same or different, a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a nitro group or a halogen atom, m denotes 1 or 2, and n denotes 1, 2 or 3, provided that, when n is 2, two R.sup.2 may be connected to each other to form a lower alkylenedioxy group), or its pharmaceutically acceptable salt. This derivative or its salt is excellent in the effect of inhibiting the expression of action of androgen, thereby being excellent in therapeutical effect of benign prostatic hypertrophy, prostatic carcinoma, etc., and has a long lasting of efficacy and high oral absorption.Type: GrantFiled: January 17, 1995Date of Patent: May 14, 1996Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Hiroshi Kiyokawa, Satoshi Yamada, Keisuke Miyajima, Koji Edamatsu, Kunihiko Tatsumi, Takeshi Yamauchi, Kazumasa Kishi, Kunihiko Kiyono
-
Patent number: 5409928Abstract: This invention provides a condensed pyrazole derivative of the Formula (1): ##STR1## (where A denotes CH or N, R.sup.0 and R.sup.3 denote same or different, a hydrogen atom or a lower alkyl group, R.sup.1 and R.sup.2 denote same or different, a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a nitro group or a halogen atom, m denotes 1 or 2, and n denotes 1, 2 or 3, provided that, when n is 2, two R.sup.2 may be connected to each other to form a lower alkylenedioxy group), or its pharmaceutically acceptable salt. This derivative or its salt is excellent in the effect of inhibiting the expression of action of androgen, thereby being excellent in therapeutical effect of benign prostatic hypertrophy, prostatic carcinoma, etc., and has a long lasting of efficacy and high oral absorption.Type: GrantFiled: October 20, 1993Date of Patent: April 25, 1995Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Hiroshi Kiyokawa, Satoshi Yamada, Keisuke Miyajima, Koji Edamatsu, Kunihiko Tatsumi, Takeshi Yamauchi, Kazumasa Kishi, Kunihiko Kiyono